Nebius crowns the AI that could save lives in healthcare

Introduction: when the AI cloud becomes a medical accelerator

An awards ceremony unveiled in London, with global repercussions

The Dutch company Nebius, listed under the ticker NBIS and specializing in cloud infrastructure for artificial intelligence, unveiled on July 1, 2026 in London the winners of the second edition of its AI Discovery Awards, an annual competition rewarding young companies that use AI to accelerate breakthroughs in healthcare and life sciences. According to Business Wire, the event gathered dozens of founders, researchers and investors presenting projects ranging from imaging diagnostics to new drug discovery.

This initiative, launched for the first time in 2025, illustrates a deep trend the West has every interest in encouraging: the convergence of massive computing power and applied biomedical research, at a time when the global race for artificial intelligence is intensifying against strategic rivals determined to close their technological gap.

Five categories, fifteen main winners and expanded global reach

Unlike the inaugural 2025 edition, which had four categories, this second edition now has five: Biopharma, Digital Health, Genomics, Medical Devices and Medical Imaging. Each category crowned three winners, receiving respectively $100,000, $50,000 and $30,000 in compute and inference credits on the Nebius AI Cloud infrastructure.

A new and significant development for 2026: Nebius also introduced regional prizes called Regional Trailblazer, rewarding promising companies in Africa, the Asia-Pacific region, Europe, the Middle East, Latin America and North America, each receiving $30,000 in additional compute credits.

The winners redefining imaging diagnostics

Real Time Imaging Systems and Nucleo Research lead the pack

In the Medical Imaging category, Nucleo Research took first place, followed by Subtle Medical and Hertility Health. In the Medical Devices category, Real Time Imaging Systems won first prize, ahead of BAIBYS Fertility and Fluent, according to the official winners list published by Nebius.

These technologies, though technically complex, pursue a clear objective: speeding up and improving the reliability of medical diagnosis through algorithms capable of analyzing radiological or pathological images with a precision and speed the human eye alone cannot match, particularly in regions of the world suffering from a shortage of qualified specialists.

Corti.ai and the quiet revolution in digital health

In the Digital Health category, Corti.ai took first place, ahead of VitVio and EverEx. These platforms use artificial intelligence to transform clinical workflows, notably through automated patient interaction and real-time analysis of medical data, a sector booming since the post-pandemic acceleration of digitization across Western health systems.

This category illustrates well the philosophy of the competition: rewarding not only spectacular scientific breakthroughs, but also pragmatic tools capable of immediately improving the daily efficiency of often-overwhelmed medical staff in Western hospitals.

Genomics and biopharma, spearheads of innovation

Omniscope and Phylo, two ambitious scientific bets

The Genomics category was won by Omniscope, ahead of Twig Bio and DELFI Diagnostics, while the Biopharma category crowned Phylo in first place, followed by Virgo and Decoy Therapeutics. These companies harness the massive computing power provided by Nebius to accelerate research processes that historically took years of traditional lab work.

The genomics category in particular illustrates the scale of applied AI's transformative potential: mapping complex genetic variations across entire populations is now possible at a speed that would have seemed unrealistic just a decade ago.

Continuity with the inaugural 2025 edition

At the first edition held in June 2025, Nebius had already rewarded companies such as Ataraxis AI, whose cancer treatment prediction platform achieved accuracy 30% higher than standard genomic tests, clinically validated on more than 7,500 patients across 15 institutions. This continuity between the two editions shows the competition is not a one-off media stunt, but part of a lasting strategy to support biomedical innovation.

The number of applications also grew, rising from 257 at the first edition to an expanded pool of international participants for 2026, a tangible sign of the competition's growing credibility within the global health start-up ecosystem.

Why compute infrastructure is becoming the backbone of scientific competition

GPU credits that sometimes matter more than traditional funding

For many young life sciences companies, access to sufficient computing power is often a more limiting obstacle than traditional venture capital funding. The compute credits offered by Nebius, reaching up to $100,000 for top places, allow these companies to train large-scale artificial intelligence models without devoting a disproportionate share of their limited capital to technical infrastructure.

This approach, combining public recognition with concrete material support, sets the Nebius competition apart from mere honorary ceremonies: it offers a real, immediately usable competitive advantage to the winning companies in their race against better-funded rivals.

European infrastructure gaining ground against American giants

Dr. Ilya Burkov, global head of growth for life sciences and healthcare at Nebius, with more than 15 years of experience spanning clinical medicine, biotechnology and cloud computing, embodies the company's ambition to position itself as a credible European alternative to American cloud computing giants. Nebius has also recently expanded its presence in the United Kingdom with one of the country's first advanced NVIDIA infrastructure deployments.

This European geographic expansion fits into a broader context in which the West is seeking to reduce its excessive dependence on a limited number of AI infrastructure providers, a diversification deemed strategically sound given the growing concentration of the global advanced-computing market.

A geopolitical stake disguised as an innovation contest

The global race for health-applied AI is accelerating

Behind the philanthropic facade of this competition lies a broader geopolitical stake: the global race to dominate the application of artificial intelligence to human health. China is investing massively in this sector, seeking to combine its vast national medical databases with its growing advanced computing capabilities, a strategy that worries several Western analysts regarding data security and biomedical intellectual property.

Facing this competition, initiatives like Nebius's strengthen the Western ecosystem's ability to quickly identify and support the most promising innovations, before they are captured or replicated by rival state actors less concerned with Western ethical standards on personal medical data protection.

Academic partnerships that consolidate the Western ecosystem

Several winners and honorable mentions from previous editions of the Nebius competition have established partnerships with prestigious academic institutions, including Microsoft Research and leading university hospital centers. These collaborations strengthen an integrated Western ecosystem where academic research, venture capital and advanced cloud infrastructure work together rather than in separate silos.

This structural integration is, in my view, one of the West's genuine lasting competitive advantages against the more centralized, less collaborative models adopted by certain international technology rivals.

Persistent challenges despite the technological enthusiasm

Clinical validation before commercial celebration

Despite the legitimate enthusiasm sparked by this awards list, it is worth recalling that most of the honored technologies remain at early development stages, still requiring rigorous clinical validation before any large-scale deployment in Western public health systems. Recent history of AI applied to medicine is full of examples of technologies that looked promising in the lab but failed to deliver in broader clinical trials.

This methodological caution takes nothing away from the merit of the winning companies, but it usefully reminds us that the path from a prototype honored at a London ceremony to a medical tool actually deployed to millions of patients remains long, costly and strewn with legitimate regulatory obstacles.

The sensitive question of medical data protection

The rapid rise of these technologies also raises legitimate questions about the protection of personal medical data used to train these artificial intelligence models. European regulators, already vigilant on these issues through strict regulatory frameworks, will need to continue adapting their oversight mechanisms as these technologies grow in sophistication and widespread clinical adoption.

A careful balance between encouraging innovation and rigorously protecting personal data remains essential to preserve Western public trust in these emerging medical technologies, a trust that is itself a competitive advantage our less privacy-scrupulous rivals do not necessarily possess.

The role of independent judges in the competition's credibility

A panel drawn from biotech, pharma and venture capital

The competition's scientific credibility rests largely on its panel of independent judges, composed at the inaugural edition of 19 experts drawn from major biotechnology, pharmaceutical and specialized venture capital firms. This diversity of expertise allows applications to be assessed on scientific, clinical and commercial criteria alike, reducing the risk of rewarding projects that look appealing on paper but lack real practical viability.

This evaluative rigor sets the Nebius competition apart from mere technology public-relations exercises: it reflects a serious intent to identify innovations with genuine clinical impact potential, rather than impressive but sterile technology demonstrations.

Honorable mentions that widen the talent-spotting net

Beyond the main winners, the competition also grants honorable mentions to dozens of additional companies, allowing a much broader pool of emerging talent to be identified than the official podium alone could reflect. This expanded approach benefits the entire ecosystem, even companies not selected among the top three in each category.

This relative generosity in talent identification bolsters the competition's reputation among venture capital investors, who now regularly consult the full list of honorable mentions to spot future investment opportunities in the digital health sector.

Nebius's expansion, from raw compute to sector specialization

From a mere GPU provider to a strategic sector partner

Nebius has profoundly transformed its business positioning over the past two years, moving from a simple provider of raw computing power to a strategic sector-specific partner, with healthcare and life sciences now an explicitly prioritized focus for the company's leadership. This specialization allows Nebius to differentiate itself from competitors offering more generalist infrastructure less suited to the specific needs of biomedical research.

Client companies such as Prima Mente, which develops foundation models to understand the human brain, or Helical, which helps pharmaceutical companies accelerate their virtual experiments, concretely illustrate this sector-specialization strategy embraced by Nebius.

An NVIDIA partnership that strengthens the European position

Nebius announced in March 2026 an expanded partnership with NVIDIA aimed at strengthening its large-scale cloud infrastructure dedicated to artificial intelligence, a collaboration that further consolidates the company's technical credibility with demanding institutional clients in the healthcare sector. This technical alliance lets Nebius offer compute capabilities comparable to those of the largest American providers, while retaining European governance and data centers.

This combination of cutting-edge American technology and European governance could prove particularly reassuring for European health companies eager to meet strict regulatory data-protection requirements while benefiting from world-class computing power.

Conclusion: a modest showcase, but an encouraging signal

What this awards list really reveals about the state of Western innovation

Beyond company names still little known to the general public, this AI Discovery Awards list reveals a living Western innovation dynamic, geographically diverse and methodologically rigorous. The combination of generous compute infrastructure, validation by an independent panel of judges drawn from biotechnology and finance, and expanded international reach outlines a replicable model other Western technology players would do well to imitate.

This dynamic, however modest it may appear compared with the spectacular announcements of American tech giants, illustrates the continued vitality of the Western innovation ecosystem applied to human health.

A milestone to watch to gauge the winners' real maturation

The real test of this competition will play out in the coming years, when observers will be able to measure how many of these honored companies have actually turned their promising prototypes into medical solutions concretely deployed to real patients. The 2025 edition had already identified companies such as Ataraxis AI, whose clinical progress deserves close monitoring in the coming months.

For now, this 2026 awards list confirms that the West retains a real methodological and institutional lead in applying artificial intelligence to healthcare, an advantage it will nonetheless need to keep actively cultivating against increasingly determined international competition.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my acknowledged biases

I am a columnist, not an artificial intelligence engineer or a biotechnology researcher. I hold a bias favorable to Western technological leadership against its strategic rivals, which colors my enthusiasm for this kind of initiative. I am not affiliated with Nebius or any of the winning companies mentioned in this text.

What I don't know and my method

I do not have access to the detailed clinical data of the winning companies or to their precise financial situation. My method consisted of cross-referencing Nebius's official press release with several media sources and the company's official website before formulating my analysis and the personal opinion expressed in this text.

Sources

Primary sources

Nebius celebrates healthcare and life sciences innovators at expanded AI Discovery Awards — Business Wire, July 1-2, 2026

AI Discovery Awards 2026 — Nebius, 2026

Nebius celebrates healthcare and life sciences — Yahoo Finance, July 2, 2026

Secondary sources

Nebius has named the winners of its inaugural AI Discovery Awards — Nebius Newsroom, June 2025

Cloud for Scientific AI and Healthcare — Nebius

Nebius AI Cloud arrives in UK with advanced NVIDIA infrastructure — MarketScreener, November 2025